Stocktoria
INTENSITY THERAPEUTICS, INC. INTS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2023-06-30
INTENSITY THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $6.8M | $10.5M | $4.8M | $5.1M |
| Operating income | -$12.0M | -$16.6M | -$8.3M | -$7.5M |
| Interest expense | — | — | $305,000 | $82,000 |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$11.6M | -$16.3M | -$10.5M | -$7.6M |
| EPS (diluted) | $-8.56 | $-29.24 | $-1.38 | $-2.22 |
| Operating cash flow | -$9.2M | -$15.2M | -$7.2M | -$5.5M |
| Cash & equivalents | $11.9M | $2.6M | $8.6M | $1.3M |
| Total assets | $14.1M | $4.8M | $17.3M | $1.8M |
| Total liabilities | $2.2M | $1.9M | $4.1M | $6.9M |
| Shareholders' equity | $11.9M | $2.9M | $13.2M | -$15.1M |
Source: SEC EDGAR filings · CIK 0001567264 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.